Atea Pharmaceuticals, Inc. (AVIR) FinancialsAVIRAtea Pharmaceuticals, Inc.

Evaluating the bottom line, Atea Pharmaceuticals, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -58.14%, provide a clear picture of how effectively AVIR converts its operational activities into shareholder value.

In the context of the broader market, AVIR competes directly with industry leaders such as ARCT and CMPX. With a market capitalization of $429.10M, it holds a leading position in the sector. When comparing efficiency, AVIR's gross margin of N/A stands against ARCT's 100.00% and CMPX's N/A. Such benchmarking helps identify whether Atea Pharmaceuticals, Inc. is trading at a premium or discount relative to its financial performance.

Atea Pharmaceuticals has a forward P/E ratio of 0, indicating no current earnings expectations, and a price-to-sales ratio of 2.27, suggesting moderate valuation relative to sales. However, the company has been consistently reporting negative net income, with the latest quarter showing a loss of $33 million.